ATYRaTyr Pharma Inc. Common Stock
0.5015USD-5.87%Mkt Cap: 49.19M $P/E: —3d ago
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the Uni…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
| Headline | Source | Time |
|---|---|---|
Older | ||
Update: ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans (Updates with restructuring information in the last three paragraphs.) ATyr Pharma (ATYR) reporte | MMT Newswires | |
 What It Means To Hold Moderna Stock In A Crash The company's pipeline is more advanced than ever, but its history shows a pattern of deep, prolonged drops when the market turns. | ||